Risdiplam is the one orally administered drug approved to the treatment method of SMA. It was FDA authorized in 2020 to be used in individuals two months of age and older, and it features being an SMN2 gene splicing modifier leading to greater amounts of SMN protein. Oral administration is https://ghomsheib974ptz6.livebloggs.com/profile